Posts by: Santiago Gisler

News

Gait speed, measured by the four meter gait speed (4MGS) test, is an independent predictor of all-cause mortality and hospitalization in patients with idiopathic pulmonary fibrosis (IPF), according to ... Read more

December 10, 2018December 10, 2018

Veracyte Expands Early Access to Envisia Genomic Classifier Test for IPF Diagnosis

News

Veracyte recently announced the expansion of an early access program offering the Envisia Genomic Classifier test for the diagnosis of idiopathic pulmonary fibrosis (IPF). In the U.S., 20 medical centers ... Read more

December 4, 2018December 4, 2018

Late-stage IPF Patients Have Progressively Worse Quality of Life, Real-world Study Reports

News

Idiopathic pulmonary fibrosis (IPF) patients experience a significant decline in quality of life and worse symptom burden during the last months of life, a real-world study shows. The Finland-based ... Read more

November 13, 2018November 13, 2018

Ouabain Treatment Reduces Idiopathic Pulmonary Fibrosis Symptoms in Mice

News

A plant-derived compound called ouabain is a potential treatment for idiopathic pulmonary fibrosis (IPF), according to a recent study. Treatment with ouabain — more commonly used to treat certain heart ... Read more

Posts by: Santiago Gisler

Santiago Gisler

4MGS Test Predicts IPF Patient Mortality, Hospitalization, Study Says

Veracyte Expands Early Access to Envisia Genomic Classifier Test for IPF Diagnosis

Late-stage IPF Patients Have Progressively Worse Quality of Life, Real-world Study Reports

Ouabain Treatment Reduces Idiopathic Pulmonary Fibrosis Symptoms in Mice

Pin It on Pinterest